Kirin Holdings Co., Ltd.

New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stagesPRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and The XLH Network, a non-profit patient advocacy organization, today announced the launch of the XLH Community Guidebook, a comprehensive online resource for patients and their caregivers living with X-linked hypophosphatemia (XLH), a rare, progressive, genetic disease that impacts the bones and muscles in both children and adults.1 People affected by XLH, their families, and experts helped develop the Guidebook as a first-of-its-kind, community-informed resource that provides information tailored for each stage of the XLH journey, from childhood through adulthood. Through practical tips and evidence-based resources, the Guidebook aims to support people navigating the everyday realities of living with XLH. It is available at www.XLHguidebook.com. “XLH can affect multiple generations within families, underscoring the need for guidance, connection, and support at every stage of life,” said Susan Faitos, Executive Director of The XLH Network. “Created with the community, for the community, we designed this Guidebook to stay useful, relevant, and responsive to the real experiences and needs of people living with XLH. We will review and update the Guidebook over time, as knowledge expands, care evolves, and our community continues to learn from one another.” While the XLH Community Guidebook began as a joint effort between the XLH Network and Kyowa Kirin, future editions will be managed solely by the XLH Network following the site's transition at the end of 2026. A Comprehensive Solution to a Longstanding Need Until now, no single resource has addressed the real-world challenges of living with XLH by providing individuals with actionable strategies for coordinating care, moving through key transitions, and engaging with the broader XLH community. The Guidebook addresses community-identified needs and insights, including learnings from the XLH Community Impact Survey. XLHers can explore the Guidebook by topic or age group, making it a practical resource they can return to as their needs evolve over time. The Guidebook content spans topics such as understanding and managing XLH symptoms, coordinating specialized medical and dental care, fostering physical and emotional well-being, and planning for key transitions for care and life, including school and work, among others. Together, these resources may help prevent care gaps over time. “The voices, experiences, and needs of people living with XLH and the families who support them every day shaped the XLH Community Guidebook,” said Eslie Dennis, Global Head of Medical Affairs, Kyowa Kirin Co., Ltd. “We’re grateful for our partnership with The XLH Network and for the contributions of community members and clinical experts who helped bring this Guidebook to life. Through this effort we hope people feel more informed, supported, and connected throughout their journey.” About X-linked hypophosphatemiaX-linked hypophosphatemia is a rare, lifelong, genetic disease that can impact the bones and muscles in both children and adults.1 In individuals with XLH, the body doesn't hold on to enough phosphorus, which is an essential mineral for bone health.1 This is due to the production of excess fibroblast growth factor 23 (FGF23), causing the body to release too much phosphorus through the urine.1 When phosphorus levels are too low (hypophosphatemia), it can cause the softening and weakening of growing bone in children (rickets) and of mature bone in children and adults (osteomalacia).1 In children, XLH typically appears as bowed legs or knock knees.1 Over time, bone weakening can lead to impaired growth and short stature.1 In adults, XLH may cause osteomalacia, fractures, and pseudo-fractures.1 About The XLH NetworkThe XLH Network supports families and individuals living with X-Linked Hypophosphatemia (XLH). Our mission includes promoting awareness and education, providing opportunities for connection and community, and fostering the search for a cure. Our vision is early, accurate diagnosis; readily available, well-managed treatment; and healthy quality of life for people living with XLH and related disorders. You can learn more about the XLH Network at XLHnetwork.org. About Kyowa Kirin Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by severe and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at kyowakirin.com or LinkedIn: Kyowa Kirin Inc. U.S. 1Dahir K, et al. X-linked hypophosphatemia: a new era in management. J Endocr Soc. 2020;4(12):bvaa151. Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/65da8fdf-5433-4eae-9648-da564875f01c https://www.globenewswire.com/NewsRoom/AttachmentNg/51b917fc-6001-4667-9c5d-30c6c13a4c13 Contact: Susan Thiele Head of Therapeutic Communications, North America susan.thiele.38@kyowakirin.com

Kyowa Hakko to present emerging research on its branded citicoline's acute effects on brain activity and cognitive performance at the 2026 ISSN Conference NEW YORK, June 17, 2026 /PRNewswire/ -- Kyowa Hakko USA, a global leader in health ingredients innovation, will present new proof-of-concept research on Cognizin® Citicoline at the upcoming International Society of Sports Nutrition (ISSN) Annual Conference. The study, which explored the acute, single-dose effects of Cognizin on brain wave activity and cognitive performance in healthy adults, adds to the growing body of evidence supporting the branded ingredient's role in cognitive health formulations. Cognizin is among the most clinically validated ingredients in the cognitive health space, with decades of research demonstrating its ability to support focus, mental energy, attention, and memory. While its benefits following extended supplementation are well established, this new randomized, double-blind, placebo-controlled crossover study investigated whether meaningful changes in cognitive function and neuroelectric activity could be observed following just a single dose. The study assessed the effects of a 500 mg dose of Cognizin versus placebo in healthy male adults, measuring outcomes across electroencephalogram (EEG) brain wave analysis, validated cognitive performance tasks, and subjective mood and affect assessments. Participants were evaluated at 60 and 240 minutes post-ingestion, providing insight into both the onset and duration of potential cognitive effects. "This study is an exciting step forward for the Cognizin research portfolio," said Katie Emerson, PhD(c), RD, CISSN, senior manager of scientific affairs, Kyowa Hakko USA. "By exploring the acute effects of a single dose, we're gaining new insight into how quickly Cognizin® may begin to support brain function — which has meaningful implications for product development across cognitive health, sports nutrition, and functional food and beverage applications." Complete study findings, including a deep dive into the study methodology, neurophysiological findings, and what the data means for the future of cognitive health ingredient science, will be revealed at the 2026 ISSN Annual Conference in a 30-minute oral presentation titled "Fueling Focus: Acute Cognizin® Effects on Brain Activity and Cognitive Performance." The session will be presented by Emerson and Tim N. Ziegenfuss, PhD, CSCS, FISSN, CEO of The Center for Applied Health Sciences and Past President of ISSN. For formulators and brand owners evaluating ingredient options in the cognitive health category, this research underscores Kyowa Hakko's continued investment in rigorous clinical science — an important differentiator in an increasingly crowded cognitive health market. More information about Cognizin is available at Cognizin.com and Kyowa-USA.com. About Kyowa Hakko USA (Kyowa) Kyowa Hakko USA serves as the North and South American headquarters for Kyowa Hakko Bio Co., Ltd., a global pioneer in specialty ingredients within Kirin Holdings' Health Science group. Building on over 75 years of fermentation innovation and Kirin's 100+ year legacy of fermentation excellence, Kyowa delivers premium, science-backed branded ingredients to the nutraceutical, pharmaceutical, functional food, beverage, and wellness industries. The portfolio features branded solutions like Cognizin® Citicoline, Setria® Glutathione, Pantesin® Pantethine, and EYEMUSE® Lacticaseibacillus paracasei KW3110. Committed to quality, sustainability, and creating shared value, Kyowa empowers partners to create transformative health solutions, advancing Kirin's vision of improving health and well-being. For more information, visit Kyowa-USA.com. About Cognizin ® Citicoline Cognizin® Citicoline, developed by Kyowa Hakko Bio Co., Ltd., is a clinically patented form of citicoline with over 35 years of research, development, and application experience. Backed by Kyowa's 75-year legacy of biotech innovation and Kirin Holdings' century-long fermentation expertise, Cognizin® is produced through state-of-the-art fermentation technology, ensuring superior purity and quality. Clinically tested to support mental energy, focus, attention, and memory, this premium functional ingredient is GRAS, pure, allergen-free, and highly stable. Trusted by global partners in the nutraceutical and wellness sectors, Cognizin® advances Kirin's Health Science mission to enhance quality of life through cognitive health solutions. For more information, visit Cognizin.com. SOURCE Kyowa Hakko U.S.A 21% more press release views with Request a Demo

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – – High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing – – Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively – – 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare favorably to 7+3 precedents and strengthen confidence in ongoing KOMET-017 Phase 3 registrational study – – Kura to host a virtual investor event tomorrow, June 12, 2026, at 8:00 a.m. ET / 5:00 a.m. PT – SAN DIEGO and TOKYO, June 11, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced encouraging long-term results from the Phase 1/2 KOMET-007 single-arm trial ( NCT05735184 ) evaluating ziftomenib in combination with intensive chemotherapy, 7+3, in newly diagnosed NPM1 -m or KMT2A -r AML. These results will be presented at the European Hematology Association 2026 Congress. These data compare favorably to historical standard-of-care data with 7+3 alone: NPM1 -m Patients KOMET-007 1 Historical 7+3 Benchmark CR Age ≤ 65 years Age > 65 years 91% (31/34) 100% (15/15) 88% 2 56% 2 CRc 96% 56-89% 2 , 3 , 4 CR MRD- ( bone marrow) 56% 44% 5 12-month OS rate 94% ~ 70-80% in younger fit patients 3 ,4 , 5 ~ 45-55% in patients > 65 years old 2 , 6 1 KOMET-007 (N=49) at 600 mg ziftomenib; MRD neg 480 msec. Perform an ECG at least once weekly for the first four weeks on treatment, and at least monthly thereafter. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms (Grade 3). In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use of KOMZIFTI with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation, result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsades de Pointes, other serious arrhythmias, and sudden death. Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 3 months after the last dose. ADVERSE REACTIONS Fatal adverse reactions occurred in 4 (4%) patients who received KOMZIFTI, including 2 with differentiation syndrome, 1 with infection, and 1 with sudden death. Serious adverse reactions were reported in 79% of patients who received KOMZIFTI. Serious adverse reactions occurring in ≥ 5% of patients included infection without an identified pathogen (29%), febrile neutropenia (18%), bacterial infection (16%), differentiation syndrome (16%), and dyspnea (6%). Dosage interruption of KOMZIFTI due to an adverse reaction occurred in 54% of patients. Adverse reactions that required dose interruption in ≥ 2% of patients included infection without an identified pathogen (15%), differentiation syndrome (13%), febrile neutropenia (5%), pyrexia (4%), electrocardiogram QT prolonged (4%), leukocytosis (4%), bacterial infection (3%), cardiac failure (2%), cholecystitis (2%), diarrhea (2%), pruritus (2%), and thrombosis (2%). Dose reduction of KOMZIFTI due to an adverse reaction occurred in 4% of patients. Permanent discontinuation of KOMZIFTI due to an adverse reaction occurred in 21% of patients. Adverse reactions that required permanent discontinuation of KOMZIFTI in ≥ 2% of patients were infection without an identified pathogen (8%), bacterial infection (4%), cardiac arrest (2%), and differentiation syndrome (2%). Most common (≥ 20%) adverse reactions, including laboratory abnormalities , were aspartate aminotransferase increased (53%), infection without an identified pathogen (52%), potassium decreased (52%), albumin decreased (51%), alanine aminotransferase increased (50%), sodium decreased (49%), creatinine increased (45%), alkaline phosphatase increased (41%), hemorrhage (38%), diarrhea (36%), nausea (35%), fatigue (34%), edema (30%), bacterial infection (28%), musculoskeletal pain (28%), bilirubin increased (27%), potassium increased (26%), differentiation syndrome (26%), pruritus (23%), febrile neutropenia (22%), and transaminases increased (21%). DRUG INTERACTIONS Drug interactions may occur when KOMZIFTI is concomitantly used with: Strong or Moderate CYP3A4 Inhibitors: Monitor patients more frequently for KOMZIFTI-associated adverse reactions. Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of KOMZIFTI. Gastric Acid Reducing Agents: Avoid concomitant use of KOMZIFTI with proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), or locally acting antacids. If concomitant use with H2RAs or locally acting antacids cannot be avoided, modify KOMZIFTI administration time. Take KOMZIFTI 2 hours before or 10 hours after administration of an H2 receptor antagonist. Take KOMZIFTI 2 hours before or 2 hours after administration of a locally acting antacid. Drugs that Prolong the QTc Interval: Avoid concomitant use of KOMZIFTI. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms. USE IN SPECIFIC POPULATIONS Pregnancy: Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to starting KOMZIFTI. Lactation: Because of the potential for adverse reactions in the breastfed child, advise women not to breastfeed during treatment with KOMZIFTI and for 2 weeks after the last dose. Infertility: Based on findings in animals, KOMZIFTI may impair fertility in females and males of reproductive potential. Please see full Prescribing Information , including Boxed WARNING . Kura Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, ziftomenib’s therapeutic potential, including as a foundational backbone in frontline AML; the safety and clinical activity of adding ziftomenib to intensive chemotherapy for patients with newly diagnosed NPM1 -m or KMT2A -r AML; the potential of ziftomenib plus intensive chemotherapy to extend the benefit of menin inhibition beyond induction, reduce reliance on transplant, and deepen ziftomenib’s impact across the AML treatment continuum; and Kura’s confidence in the Phase 3 KOMET-017 trials. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at . Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Kura Contact Greg Mann (Investors and Media) 858-987-4046 gmann@kuraoncology.com Kyowa Kirin Contacts Ryohei Kawai (Investors) Kyowa Kirin ir@kyowakirin.com Sachiko Kido (Media, Global) Kyowa Kirin media@kyowakirin.com A photo accompanying this announcement is available at